15-01-2012 06:04 * The BEST Way to protect against cancer and very bad diseases is NATURE. * PREVENTION and BEING IN NATURE HARMONY are The First Things to do. * Eat ENOUGH MEAT and PLENTY FRUITS + VEGETABLES for Being Healthy. * But … what’s The Point with Cancer? Cancer is A CELULAR DISEASE. * For example, if you eat TOO MANY RAFINATED OILS (bad substance for cells which destroys by making them to auto-modify to be abel to assimilate it) That is NoT A Good Prevention. * So AVOIDING BAD FOODS and DRINKS is A Way To Prevent/Avoid Cancer. * Another Way For Preventing/Avoiding Cancer is by CONSUMING GOOD FOOD and DRINKS. There are Antioxidant Substances in foods and drinks which are BEST “TOOLS” TO FIGHT AGAINST/TO PREVENT CANCER. * Examples of Antioxidant Foods and Drinks : Sunflower Seeds
An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol. Study details available in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases, report that rituximab was successful in reducing the level of alkaline phosphatase (ALP)—a protein used to measure liver injury.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), PBC—an autoimmune liver disease characterized by inflammation of the bile ducts that ultimately causes bile to build up and damage the liver—typically occurs between the ages of 40 and 60, primarily affecting women. Medical studies have identified the presence of anti-mitochondrial autoantibodies (AMA) to enzymes involved in the production of the body's energy (pyruvate dehydrogenase complex-PDC-E2) in up to 95% of PBC cases.
Currently, the standard therapy for PBC is UDCA or liver transplantation in patients who have progressed to end-stage liver disease. However, previous studies have shown that UDCA may be ineffective in up to 40% of PBC patients and 10% could require transplantation or die from the disease. “Small trials using immunosuppressants have failed to demonstrate significant clinical benefit or carry unacceptable safety profiles,” said Dr. Christopher Bowlus with UC Davis Health System in California and lead author of the current study.
The European Society of Cardiology (ESC) welcomes an “intriguing” study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure. In the “hypothesis generating” study, ursodeoxycholic acid (UDCA) delivered significant improvements in peak post ischemic blood flow in the arm, a trend for improvement in peak post ischemic blood flow in the leg, but failed to show benefits in exercise capacity and several inflammatory markers. Despite such conflicting data, ESC spokespersons believe that further exploration of UCDA is now justified in larger populations of heart failure patients.
“Although the study failed on two out of three counts , the observed improvements in post ischemic arm and leg blood flow make it highly unlikely such findings would have occurred purely by chance,” says Professor Kenneth Dickstein, an ESC spokesperson. “The results are enough to pique real interest and suggest the approach has the potential to offer another string to our bow for improving heart failure symptoms.”
It is also noteworthy, adds Dickstein from the University of Bergen (Stavanger University Hospital, Norway), that JACC felt the study to be of sufficient merit to commission an editorial.
The theory underlying the use of UDCA (a bile acid commonly used in the treatment of cholestatic liver disease) centres on the finding that abdominal congestion (caused by heart failure) leads to increased gut permeability, allowing endotoxins produced by gram negative bacteria to enter the circulation. The increased levels of proinflammatory cytokines can then further exacerbate symptoms of heart failure. UDCA is able to form a complex (“mixed micelles”) around a component of the cell-wall of the gram-negative bacteria (lipopolysaccharide), thereby decreasing levels of proinflammatory cytokines and offering the potential to improve peripheral blood flow and ultimately increase exercise tolerance.
In the last 10 to 15 years studies have explored modifying inflammation in heart failure patients (through anti-inflammatory agents, antibiotics and statins), but all have proved neutral or in some cases even resulted in worse outcomes for patients.
19-01-2012 21:46 My pride and joy. Sara is having a wonderful birthday party dinner Vietnamese style. Take note, I am 63 and se is3. How can this happen, well, I have a secret how to maintain energy, wellness and good health. How: www.heart-disease-herbs.com.
10-09-2011 19:18 www.rhemat.stemtechbiz.com e mail chris@rhemat.co.za The Roll of Stem Cells in your Body Support the Natural Healing System of the Body
05-10-2011 13:45 stemcellremedy.com Stem Cell Remedy User Forum and Blog is a global collaborative effort of regular individuals and trained researchers from organizations across the world focused on helping patients, friends and families, while avoiding the politics associated with other types of research a The sixteenth installment of my original series, “Discovering Religion”. In this episode I discuss the current actions of Christian Americans to suppress modern-day scientific advancements. In particular, I address the movement by Christians to outlaw embryonic stem cell, a stance they have no justification from the Bible in taking — a situation that very closely parallels the Church’s suppression of Roger Bacon and Galileo Galilei’s scientific discoveries. Additional information I could not include in the video Diabetes: Giving insulin to children with Type I Diabetes is a viable means of treating this disease, however; after 15-20 years of living with type I diabetes, the danger continues to grow, possibly leading to kidney failure, heart disease, blindness, brain damage, and premature death. This is why stem cell research is so crucial to patients suffering from this serious condition. Bone Marrow Transplants: There are many patients, both child and adult, in need of bone marrow transplants that would greatly benefit from the use of stem cells. For 2/3 of them, there is no donor with an acceptable genetic match. However, even when a match is found, it is never perfect. With stem …
21-12-2011 16:16 I no longer worry about having another heart attack or high blood pressure. The way I got rid of plaque in my arteries and kidneys after my heart attack. How does your immune system effect cardiovascular disease?
A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.
23-01-2012 19:28 “Left this world a little better just because I was here.” Yesterday, the 22nd of January, marked a devastating and unforgettable day for all those who knew, loved and followed precious Layla Grace Marsh’s story as she battled fiercely against the disease that claimed her life. After a routine check-up following her stem cell transplant Layla’s parents were given the news that instead of getting better she had new tumors. Not only were they back in her abdomen but they were now crowding and invading her kidney. Her only good kidney. Precious Layla Grace was sent home with no treatment options aimed toward a cure. She was sent home to pass away. On the 9th of March, 2010 Layla gave up the fight for her “sparky” (sparkly) wings and has been her family’s guardian angel ever since. Layla was full of life, happiness, love, fearlessness, determination, spunk, wit, joy and above all, strength. She loved wearing her flower beanies, babylegs and tutus. A smile was always flashed across her cheeky little face and she would often claim that she “had a good day” despite all the shit she was going through at the time. Layla lived, she loved and her legacy on how to do this is still here. I will never forget you. Miss you, boo. This video is dedicated to my wonderful friend through Twitter, Melly. Thank you for motivating me to finish this video even if I had to “cut it off where I finished.” Seeing Layla’s face and making videos (especially those commemorating certain painful milestones) are …
13-01-2012 12:10 www.justgiving.com/vanessa-appeal In Feb 2009, Vanessa, then aged 8, was diagnosed with Stage 4 (High-Risk) Neuroblastoma, a very rare, aggressive and difficult to treat form of childhood cancer. Fewer than 100 children in the UK are diagnosed with neuroblastoma each year, most of which are below the age of 5 and generally have a better prognosis as the older the child is the worse the prognosis is. Since Feb 09, Vanessa has undergone many different treatments at Yorkhill Hospital in Glasgow, these include; 12 rounds of High Dose Chemotherapy, two 7 hour surgical operations, the removal of one of her kidneys, a stem cell transplant, Radiotherapy, Retinoic Acid treatment and Immunotherapy treatment……all of which was agonising to watch as parents never mind to have to endure as a child! Having undergone all this difficult and often very painful treatment the fact remained that due to a high relapse rate the long term prognosis for Vanessa’s survival remained very poor with less than a 40% survival rate. All the same, Vanessa finished her treatment at Yorkhill Hospital in Aug 2010 and was given the all clear. In Dec 2011 after routine scans, we were given the devastating news that Vanessa had relapsed. She has many hotspots on the skull, neck, spine, leg and knees. The UK doctors have told us that this time round there is very little chance of survival; “much less than 10%” they said, as we do not have any relapse protocols in the UK. This is due to the Government not …
KineMed, Inc. (www.kinemed.com) today announced a non-exclusive research collaboration with Pfizer Inc. (NYSE:PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed's Dynamic ProteomicsTM technology platform to map the impact of potential drug candidates on specific metabolic pathways.
“We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets”
Diabetes is an increasingly challenging global healthcare problem and in the United States affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke, and is now also the leading cause of kidney failure, non-traumatic lower-limb amputations, and new cases of blindness among adults in the United States.
Despite over 50 years of drug research, over 60% of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.
“We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets,” said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. “We are using our translational platform to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials.”
The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.
The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.
NEW YORK , Dec. 29, 2011 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Proteomics – Technologies, Markets and Companies http://www.reportlinker.com/p0203550/Proteomics—Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=GenomicsSummaryThis …
John Lawson Cullison, Jr., an artist lost his ability to paint due to the effects of arthritis. This incurable condition is due to the degeneration in cartilage tissue and symptoms include: pain, tenderness in the joints, stiffness, loss of flexibility, bone spurs and severe swelling. Pain management and joint replacement surgery are the typical means to treating this condition